Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients
Temporary mechanical circulatory support (tMCS) devices are a critical component for treating patients with cardiogenic shock (CS). We analyzed use of Impella 5.5 device for efficacy and safety in a single-center CS population from February 2022 and April 2023. Thirty-six CS patients received Impell...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/joic/7044608 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850065872439214080 |
|---|---|
| author | Ioana Dumitru Debbie Rinde-Hoffman Maria Sevillano Leeandra Schnell Elizabeth Quintilliani Swaroop Bommareddi |
| author_facet | Ioana Dumitru Debbie Rinde-Hoffman Maria Sevillano Leeandra Schnell Elizabeth Quintilliani Swaroop Bommareddi |
| author_sort | Ioana Dumitru |
| collection | DOAJ |
| description | Temporary mechanical circulatory support (tMCS) devices are a critical component for treating patients with cardiogenic shock (CS). We analyzed use of Impella 5.5 device for efficacy and safety in a single-center CS population from February 2022 and April 2023. Thirty-six CS patients received Impella 5.5 support for a median duration of 16 (2, 63) days, during a median hospital stay of 40 (4, 97) days, with an overall survival (OS) of 69%. While 18 patients received Impella 5.5 only, 11 patients received Impella 5.5 as part of a de-escalation strategy, and 7 patients escalated from Impella CP only to Impella 5.5. At the time of implant, creatinine was 1.5 (0.6, 5.2) mg/dL and normalized to 1.1 (0.6, 7.7) mg/dL at discharge. In a subset of CS transfer patients (n = 12), median duration of support was 16 (1, 31) days, duration of hospital stay was 43 (8, 88) days, and OS was 67% (8/12). Collectively, these data demonstrate that Impella 5.5 support is safe and effectively improves laboratory values and survival outcomes in both transfer and in-house patients with CS. |
| format | Article |
| id | doaj-art-337d7bf25ad0487b924c5d833a7c872d |
| institution | DOAJ |
| issn | 1540-8183 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-337d7bf25ad0487b924c5d833a7c872d2025-08-20T02:48:54ZengWileyJournal of Interventional Cardiology1540-81832024-01-01202410.1155/joic/7044608Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock PatientsIoana Dumitru0Debbie Rinde-Hoffman1Maria Sevillano2Leeandra Schnell3Elizabeth Quintilliani4Swaroop Bommareddi5Division of Advanced Heart Failure and Cardiac TransplantDivision of Advanced Heart Failure and Cardiac TransplantDivision of Advanced Heart Failure and Cardiac TransplantDivision of Advanced Heart Failure and Cardiac TransplantAbiomedDivision of Advanced Heart Failure and Cardiac TransplantTemporary mechanical circulatory support (tMCS) devices are a critical component for treating patients with cardiogenic shock (CS). We analyzed use of Impella 5.5 device for efficacy and safety in a single-center CS population from February 2022 and April 2023. Thirty-six CS patients received Impella 5.5 support for a median duration of 16 (2, 63) days, during a median hospital stay of 40 (4, 97) days, with an overall survival (OS) of 69%. While 18 patients received Impella 5.5 only, 11 patients received Impella 5.5 as part of a de-escalation strategy, and 7 patients escalated from Impella CP only to Impella 5.5. At the time of implant, creatinine was 1.5 (0.6, 5.2) mg/dL and normalized to 1.1 (0.6, 7.7) mg/dL at discharge. In a subset of CS transfer patients (n = 12), median duration of support was 16 (1, 31) days, duration of hospital stay was 43 (8, 88) days, and OS was 67% (8/12). Collectively, these data demonstrate that Impella 5.5 support is safe and effectively improves laboratory values and survival outcomes in both transfer and in-house patients with CS.http://dx.doi.org/10.1155/joic/7044608 |
| spellingShingle | Ioana Dumitru Debbie Rinde-Hoffman Maria Sevillano Leeandra Schnell Elizabeth Quintilliani Swaroop Bommareddi Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients Journal of Interventional Cardiology |
| title | Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients |
| title_full | Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients |
| title_fullStr | Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients |
| title_full_unstemmed | Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients |
| title_short | Single Center Experience With Impella 5.5 for Escalation and De-Escalation of Cardiogenic Shock Patients |
| title_sort | single center experience with impella 5 5 for escalation and de escalation of cardiogenic shock patients |
| url | http://dx.doi.org/10.1155/joic/7044608 |
| work_keys_str_mv | AT ioanadumitru singlecenterexperiencewithimpella55forescalationanddeescalationofcardiogenicshockpatients AT debbierindehoffman singlecenterexperiencewithimpella55forescalationanddeescalationofcardiogenicshockpatients AT mariasevillano singlecenterexperiencewithimpella55forescalationanddeescalationofcardiogenicshockpatients AT leeandraschnell singlecenterexperiencewithimpella55forescalationanddeescalationofcardiogenicshockpatients AT elizabethquintilliani singlecenterexperiencewithimpella55forescalationanddeescalationofcardiogenicshockpatients AT swaroopbommareddi singlecenterexperiencewithimpella55forescalationanddeescalationofcardiogenicshockpatients |